J Korean Diabetes.  2024 Mar;25(1):1-3. 10.4093/jkd.2024.25.1.1.

The Global Shortage of Glucagon-Like Peptide-1 Receptor Agonists

• Yi D

• KMID: 2554114
• DOI: http://doi.org/10.4093/jkd.2024.25.1.1

Abstract

The global shortage of glucagon-like peptide-1 (GLP-1) receptor agonists, which are highly sought after as treatments for type 2 diabetes and obesity, is increasing. This deficit is attributed to the unexpected increase in demand for GLP-1 receptor agonists. This has caused significant harm to patients with type 2 diabetes mellitus who are already using GLP-1 receptor agonists for blood sugar management, weight loss, or reduction of cardiovascular risk or those who are looking to start. To address this situation, doctors need to adjust medications considering the patient condition and clinical guidelines and must provide better education on lifestyle modifications such as diet and exercise. Close cooperation between regulatory agencies and manufacturers is needed to mass-produce GLP-1 receptor agonists, as are societal efforts to prevent the trend of GLP-1 receptor agonist use as diet pills.

Keyword

Diabetes mellitus, type 2; Glucagon-like peptide 1; Obesity

Reference

1.Beba H., Cahill K., Dhatariya K., Diggle J., Hambling C., Milne N, et al. Glucagon-like-peptide 1 receptor agonist national shortage: guidance from the Primary Care Diabetes Society (PCDS) and Association of British Clinical Diabetologists (ABCD). Available from: https://www.pcdsociety.org/pcds-abcd-guidance-glp1-shortage.

2.Whitley HP., Trujillo JM., Neumiller JJ. Special report: potential strategies for addressing GLP-1 and dual GLP-1/GIP receptor agonist shortages. Clin Diabetes. 2023. 41:467–73.

3.Korean Diabetes Association. Clinical practice guidelines for diabetes. 8th ed.Seoul: Korean Diabetes Association;2023. p. 124–77.

4.Frederick MO., Boyse RA., Braden MB., Calvin JR., Camp-bell BM., Changi SM, et al. Kilogram-Scale GMP manu-facture of tirzepatide using a hybrid SPPS/LPPS approach with continuous manufacturing. Org Process Res Dev. 2021. 25:1628–36.

5.U.S. Food & Drug Administration. ANDAs for certain highly purified synthetic peptide drug products that refer to listed drugs of rDNA origin guidance for industry: guidance for industry. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-docu-ments/andas-certain-highly-purified-synthetic-peptide-drug-products-refer-listed-drugs-rdna-origin.